SBIR/STTR Research Award

Isolation and characterization of a primary breast epithelium transforming agent

Award identifier d69209412d42b07eaef9aef62317a903baf8b26fb4c9ad415d6196f38493eb75Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$299,675

Program and phase

SBIR · Phase I

Award year

2017

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
SkinAxis LLC
Proposal award date
2017-09-25
Contract end date
2019-02-28
UEI
WR1FPNGBQ4W9
Solicitation number
PA16-302
Topic code
102

Research abstract

Abstract Breast cancer BC is the most common cancer among women Viruses have long been suspected as a cause of breast cancer However despite the identification of virions in human BC cells and human milk and numerous studies that suggest possible connection between breast cancer and Epstein Barr virus EBV mouse mammary tumor virus MMTV and human papilloma virus HPV the tumorigenic potential of these viruses has not been proven in BC Our preliminary data offer the compelling evidence that a filterable transforming agent is present in the supernatant of a BC cell line that we established in vitro This agent is transmissible transforms primary human mammary epithelial cells in vitro and confers these cells the tumorigenic phenotype in vivo Based on preliminary results we hypothesize that a virus accounts for the observed human mammary epithelial cells transforming activity This application has the very focused objective of isolating and characterizing this transforming agent employing comprehensive and complementary proteomics and transcriptomics approaches and in vitro genetic validation systems The results of this study will provide the first evidence of a human mammary epithelial cells transforming agent and shed new light into tumor pathogenesis Importantly the isolation of a BC transforming virus will allow the development of novel diagnostic tools vaccines and specific inhibitors of significant therapeutic value Cells from breast cancer tissue isolated in our laboratory release an oncogenic virus that causes tumor in primary mammary cells We will isolate and characterize this viral agent Its identification will allow the development of diagnostics vaccines and antiviral molecules to prevent or treat breast cancer

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

2 SBIR/STTR records share this UEI (2017–2022). Reported award amounts total $559,277. Reported amounts are not federal obligations.

Phases: Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.